Selected publications
-
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood.
2019
Academic Article
GET IT
Times cited: 34 - Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma. 2018 Academic Article GET IT
-
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Biology of Blood and Marrow Transplantation.
2018
Academic Article
GET IT
Times cited: 2 -
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Clinical Lymphoma, Myeloma and Leukemia.
2018
Academic Article
GET IT
Times cited: 4 -
Low Clinical Trial Accrual of Patients With Myelodysplastic Syndromes: Causes and Potential Solutions.
Cancer.
2018
Academic Article
GET IT
Times cited: 1 -
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care.
Blood Cancer Journal.
2017
Information Resource
GET IT
Times cited: 6 -
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Blood.
2017
Academic Article
GET IT
Times cited: 39 -
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Blood.
2017
Academic Article
GET IT
Times cited: 352 -
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes.
Cancer.
2017
Academic Article
GET IT
Times cited: 45 -
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*.
Leukemia and Lymphoma.
2016
Academic Article
GET IT
Times cited: 7 -
A multi-institution phase i trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML).
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 46 -
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
Haematologica.
2016
Information Resource
GET IT
Times cited: 20 -
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Leukemia Research.
2016
Academic Article
GET IT
Times cited: 11 -
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial.
The Lancet Oncology.
2016
Academic Article
GET IT
Times cited: 61 -
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Journal of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 34 -
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?.
American Journal of Hematology.
2015
Academic Article
GET IT
Times cited: 19 -
Genetic alterations of the cohesin complex genes in myeloid malignancies.
Blood.
2014
Academic Article
GET IT
Times cited: 103